Bixiye
QP80-23 Blue Cross Response to Medical Oncology Drug Shortage of Cisplatin and Carboplatin
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Natiijooyinka Raadinta
Soo bandhiga 1381 - 1390 ee natiijooyinka 5269
Bixiye
QP81-23 Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra)
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP87-23 Availity Essentials Updated Claim Entry Forms
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Warqada dawada ee dhakhtar qoray & farmashiye
Bixiye
policyii-174-med-drug-eval-process-list-2023-1001.pdf